Systematic review: Blood pressure target in chronic kidney disease and proteinuria as an effect modifier

Annals of Internal Medicine

Volumn 154, Issue 8, 2011, Pages 541-548

  Upadhyay, Ashish ^a   Earley, Amy ^a   Haynes, Shana M ^a   Uhlig, Katrin ^a  

^a Division of Nephrology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; CREATININE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; FUROSEMIDE; HYDRALAZINE; MINOXIDIL; RAMIPRIL;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; COUGHING; CREATININE CLEARANCE; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FOLLOW UP; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MEDLINE; NEPHROSCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RENOVASCULAR HYPERTENSION; REVIEW; SEXUAL DYSFUNCTION; SYNCOPE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 79955375480     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-8-201104190-00335     Document Type: Review

References (39)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
2. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. [PMID: 12748199]
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al; Management of Arterial Hypertension of the European Society of Hypertension. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187. [PMID: 17563527]
4. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1-290. [PMID: 15114537]
5. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157: 2413-2446. [PMID: 9385294]
6. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al; Japanese Society of Hypertension Committee. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3-107. [PMID: 19300436]
7. Harris D, Thomas M, Johnson D, Nicholls K, Gillin A; Caring for Australasians with Renal Impairment (CARI). The CARI guidelines. Prevention of progression of kidney disease. Nephrology (Carlton). 2006;11 Suppl 1:S2-197. [PMID: 16684077]
8. The Renal Association. The UK CKD eGuide to Hypertension. 2010. Accessed at www.renal.org/whatwedo/InformationResources/CKDeGUIDE/Hypertension.aspx on 10 January 2011.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266. [PMID: 11904577]
10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009:S1-130. [PMID: 19644521]
11. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155. [PMID: 19845597]
12. Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, et al. Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann Intern Med. 2006;145:901-912. [PMID: 17062633]
13. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5:1-56. [PMID: 11701102]
14. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007; 357:2189-2194. [PMID: 18032770]
15. Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641-650. [PMID: 9040451]
16. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-884. [PMID: 8114857]
17. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123: 754-762. [PMID: 7574193]
18. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431. [PMID: 12435255]
19. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, et al; AASK Study Group. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis. 2006;48:739-751. [PMID: 17059993]
20. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al; REIN-2 Study Group. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-946. [PMID: 15766995]
21. Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, et al; AASK Collaborative Research Group. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918-929. [PMID: 20818902]
22. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342-351. [PMID: 15738453]
23. Beck GJ, Berg RL, Coggins CH, Gassman JJ, Hunsicker LG, Schluchter MD, et al. Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group. Control Clin Trials. 1991;12:566-586. [PMID: 1664792]
24. Bria E, Di Maio M, Cuppone F, Nistico C, Cognetti F, Giannarelli D. Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice? [Letter]. J Clin Oncol. 2007;25:605-606. [PMID: 17290074]
25. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-186. [PMID: 15639301]
26. Sleight P. Debate: Subgroup analyses in clinical trials: fun to look at- but don't believe them!. Curr Control Trials Cardiovasc Med. 2000;1:25-27. [PMID: 11714402]
27. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev. 2009:CD004349. [PMID: 19588353]
28. Rosendorff C, Black HR. Evidence for a lower target blood pressure for people with heart disease. Curr Opin Cardiol. 2009;24:318-324. [PMID: 19395951]
29. Roy M, Mahmood N, Rosendorff C. Evidence for aggressive blood pressure-lowering goals in patients with coronary artery disease. Curr Atheroscler Rep. 2010;12:134-139. [PMID: 20425249]
30. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-1585. [PMID: 20228401]
31. Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol. 2010;21:1086-1092. [PMID: 20576804]
32. Luft FC. Editorial perspective. The low down on down low [Editorial]. Am J Nephrol. 2010;32:381-382. [PMID: 20814197]
33. Toto RB. Rebuttal: PRO Position. People with chronic kidney disease should have a blood pressure lower than 130/80 mm Hg. Am J Nephrol. 2010;32: 377-378.
34. Toto RB. Debate: PRO Position. People with chronic kidney disease should have a blood pressure lower than 130/80 mm Hg. Am J Nephrol. 2010;32: 370-373.
35. Agarwal R. Rebuttal: CON Position. People with chronic kidney disease should have a blood pressure lower than 130/80 mm Hg. Am J Nephrol. 2010; 32:379-380.
36. Agarwal R. Debate: CON Position. People with chronic kidney disease should have a blood pressure lower than 130/80 mm Hg. Am J Nephrol. 2010; 32:374-376.
37. ClinicalTrials.gov. SPRINT (Systolic Blood Pressure Intervention Trial). Clinical trial. Accessed at www.clinicaltrial.gov/ct2/show/NCT01206062?term=SPRINT&rank=2 on 25 January 2011.
38. ClinicalTrials.gov. HALT Progression of Polycystic Kidney Disease (HALT PKD). Clinical trial. Accessed at www.clinicaltrial.gov/ct2/show/NCT00283686?term=HALT-PKD&rank=1 on 25 January 2011.
39. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073-2081. [PMID: 20483451]